NTRA
NTRA clinical trials: Natera, Inc.
Every trial on ClinicalTrials.gov where Natera, Inc. is the lead sponsor or a listed collaborator, the trials it leads first, each labelled Lead or Collaborator. Phase, status and dates as registered.
- 81
- Trials linked
- 36
- As lead sponsor
- 45
- As collaborator
- 0
- Primary completions as lead sponsor, next 90 days
NTRA on the catalyst calendar · NTRA registry changes
- Primary completion May 15, 2032Sponsor estimateNo phase registeredNCT07214532Signatera-Guided CDK4/6 Inhibitor Therapy in Breast CancerNatera, Inc. · Breast NeoplasmsRecruitingNTRALead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Aug 2034Sponsor estimateNo phase registeredNCT07689812A Multicenter Randomized Open-Label Trial Evaluating ctDNA-Guided Interruption Versus Standard of Care Immune-Checkpoint Inhibitor (ICI)...Natera, Inc. · NSCLC (Advanced Non-small Cell Lung Cancer)Not yet recruitingNTRALead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Nov 29, 2023ActualNo phase registeredNCT05004337Verification of Risk Assignment for Whole Chromosome Using SNP-based NIPT in Vanishing Twin PregnanciesNatera, Inc. · Vanishing TwinCompletedNTRALead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Jul 2032Sponsor estimateNo phase registeredNCT07763197Sample Collection for Ongoing Research and Product Evaluation Study - Non-muscle Invasive Bladder Cancer (SCORE-NMIBC)Natera, Inc. · Non-Muscle Invasive Bladder CancerRecruitingNTRALead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Apr 2032Sponsor estimateNo phase registeredNCT07750886Sample Collection for Ongoing Research and Product Evaluation Study - Non-Hodgkin Lymphoma (SCORE-NHL)Natera, Inc. · Non-Hodgkin LymphomaRecruitingNTRALead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Dec 2027Sponsor estimateNo phase registeredNCT07718633Immunosuppression Optimization Using The Prospera Assay In Kidney Transplant Recipients (IMPAKT)Natera, Inc. · Kidney TransplantNot yet recruitingNTRALead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Oct 2034Sponsor estimateNo phase registeredNCT07339384Signatera Assessment in Early-Stage Endometrial CancerNatera, Inc. · Endometrial CancerNot yet recruitingNTRALead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Sep 2028Sponsor estimateNo phase registeredNCT07565857Signatera-Guided De-escalation of Adjuvant Therapy in Resectable Stage II-IVa Gastric/Gastric-Esophageal CancerNatera, Inc. · Gastric-Esophageal CancerNot yet recruitingNTRALead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Apr 2027Sponsor estimateNo phase registeredNCT06808880EXpanding Prenatal Cell Free DNA Screening Across moNogenic Disorders (EXPAND)Natera, Inc. · Single Gene NIPTRecruitingNTRALead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Feb 2027Sponsor estimateNo phase registeredNCT06414603A Comparative Effectiveness Study in Heart Transplant Patients of Rejection Surveillance With Cell-free DNA Versus Endomyocardial BiopsyNatera, Inc. · Heart Transplant Failure and RejectionActive, not recruitingNTRALead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Jan 2035Sponsor estimateNo phase registeredNCT07318051Sample Collection for Ongoing Research and Product Evaluation StudyNatera, Inc. · Breast CancerRecruitingNTRALead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Jul 10, 2027Sponsor estimateNo phase registeredNCT07046585Evaluation of the Natera Colorectal Cancer Screening Test in an Average Risk Population (FIND-CRC)Natera, Inc. · Colo-rectal CancerRecruitingNTRALead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Oct 31, 2026Sponsor estimateNo phase registeredNCT05205551Prospera Test Evaluation in Cardiac Transplant (ProTECT)Natera, Inc. · Heart Transplant RejectionActive, not recruitingNTRALead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Aug 2026Sponsor estimateNo phase registeredNCT05170425LAMBDA 002 (Lung Registry) StudyNatera, Inc. · Lung Transplant RejectionActive, not recruitingNTRALead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Aug 23, 2024ActualNo phase registeredNCT03984747Study for the Prediction of Active Rejection in Organs Using Donor-derived Cell-free DNA DetectionNatera, Inc. · Transplant RejectionCompletedNTRALead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Jul 31, 2025Sponsor estimateNo phase registeredNCT06620627Prospective Collection of Samples to Enable the Development of Natera Screening Assay for Early Cancer DetectionNatera, Inc. · Colorectal Cancer ScreeningRecruitingNTRALead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Oct 2, 2024ActualNo phase registeredNCT05309382Development of Non-invasive Cell-free DNA to Supplant Invasive Biopsy in Heart TransplantationNatera, Inc. · Heart TransplantCompletedNTRALead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion May 15, 2023ActualNo phase registeredNCT05312814Clinical Utility of the Addition of a SNP-based NIPT Zygosity Determination in Twin Pregnancy Management.Natera, Inc. · Twin to Twin Transfusion SyndromeCompletedNTRALead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Dec 31, 2023ActualNo phase registeredNCT04761783BESPOKE Study of ctDNA Guided ImmunotherapyNatera, Inc. · Colorectal CancerCompletedNTRALead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Oct 1, 2026Sponsor estimateNo phase registeredNCT04091984The PROspera Kidney Transplant ACTIVE Rejection Assessment Registry (ProActive)Natera, Inc. · Kidney Transplant RejectionActive, not recruitingNTRALead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Jan 2025Sponsor estimateNo phase registeredNCT05081739Donor-Derived Cell-free DNA to DETect REjection in Cardiac TransplantationNatera, Inc. · Heart Transplant Failure and RejectionWithdrawnNTRALead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Sep 2025Sponsor estimateNo phase registeredNCT04264702BESPOKE Study of ctDNA Guided Therapy in Colorectal CancerNatera, Inc. · Colorectal CancerUnknown statusNTRALead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Aug 2025Sponsor estimateNo phase registeredNCT05846113Renasight Clinical Application, Review and Evaluation (RenaCARE) StudyNatera, Inc. · Kidney DiseasesUnknown statusNTRALead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Apr 2014ActualNo phase registeredNCT01545674Prenatal Non-invasive Aneuploidy Test Utilizing SNPs TrialNatera, Inc. · Trisomy 13TerminatedNTRALead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Jun 2020ActualNo phase registeredNCT02381457SNP-based Microdeletion and Aneuploidy RegisTry (SMART)Natera, Inc. · 22q11 Deletion SyndromeCompletedNTRALead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
Enrollment, interventions and the start and completion dates are locked on 25 rows here. Included with TrialScanner ($9.99 a month) and Signal8 Pro.
Unlock with TrialScannerShowing the first 25 trials. There are 56 more in this window; the full list is part of TrialScanner.
Unlock with TrialScanner